Abstract: According to one embodiment, a platooning operation system organizes a platoon by making a plurality of vehicles cooperate. The platooning operation system includes an application acceptance processor and a platoon organization processor. The application acceptance processor accepts an application of a vehicle for admission to the platoon. The platoon organization processor which selects a platoon to which the vehicle is to be admitted or determines possibility of admission of the vehicle to the platoon, based on at least one of information on a driver driving the vehicle and information on the vehicle.

Abstract: A thermal transfer sheet including a substrate and a transfer layer on the substrate in this order in the thickness direction, the transfer layer being peelable by thermal transfer, wherein the transfer layer includes an electrically conductive layer or metal-containing layer and an adhesive layer, the adhesive layer contains at least one component selected from a modified polyolefin and an ionomer, and the electrically conductive layer or the metal-containing layer constitutes a surface layer on the substrate side of the transfer layer.

Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.

Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.

Abstract: Provided are a liquid preparation wherein the pharmaceutically active ingredient is stabilized, and a stabilizing method therefor. A liquid preparation comprising a pharmaceutically active ingredient having a primary or secondary amino group (wherein the amino group does not constitute a part of the amide structure), an organic acid and a salt, which is substantially free of a reaction product of the pharmaceutically active ingredient and the organic acid.

Abstract: A thermal transfer sheet is provided, which allows for forming an image favorable to any transfer objects having a poor smoothness or a high smoothness. The thermal transfer sheet according to the present invention includes a substrate, and a transfer layer. The transfer layer includes a release layer, a colorant layer and an adhesive layer. The release layer includes a polyethylene glycol having a number average molecular weight Mn in a range of 8000 or more to 23000 or less, and the colorant layer includes a colorant and a vinyl chloride-vinyl acetate copolymer.

Abstract: Provided is a thermal transfer sheet that can form a good image on both a transfer object made of a polyethylene terephthalate and a transfer object made of a polypropylene, as well as can form an image with high alcohol resistance. The thermal transfer sheet of the present invention includes a substrate, and a transfer layer including a colored layer and an adhesive layer, in which the adhesive layer has a phase-separated structure formed by a polyester and a polyolefin that are incompatible with each other, and in which the percentage of the region formed by one of the polyester and the polyolefin to the total area (100%) of the adhesive layer is 55% or more and 85% or less.

Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.

Abstract: Provided is a stable pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, and the like. In the pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, citric acid, phosphoric acid, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid or trishydroxymethyl aminomethane is added as a buffering agent, sucrose or glycerin is added as a stabilizer, a nonionic surfactant is added, and the pH is adjusted to 6.5 to 7.5. This enables suppression of generation of multimers and insoluble subvisible particles during preservation of the labeling moiety-anti-human antibody Fab fragment conjugate.

Abstract: Provided is a stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants, or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.

Abstract: [Object] An object is to provide a thermal transfer sheet which allows for forming an image favorable to any of transfer objects having a poor smoothness and a high smoothness. [Solution] The thermal transfer sheet according to the present invention comprising: a substrate; and a transfer layer comprising a release layer, a colorant layer and an adhesive layer, wherein the release layer includes a polyethylene glycol having a number average molecular weight of 8000 or more and 23000 or less and the colorant layer includes one or both of a polyester and a vinyl chloride-vinyl acetate copolymer, and a colorant.

Abstract: A toner having chargeability and fluidity that do not change to a great extent is provided. The toner includes toner particles containing a binder resin and includes inorganic fine particles A, wherein the shape factor SF-2 of primary particles of the inorganic fine particles A is 116 or less, and regarding the particle size distribution on a volume basis of the inorganic fine particles A on the toner particle surfaces, the particle diameter when a cumulative value from the small particle side reaches 16% by volume is denoted as D16, the particle diameter when a cumulative value reaches 50% by volume is denoted as D50, and the particle diameter when a cumulative value reaches 84% by volume is denoted as D84, D50 is 80 nm or more and 200 nm or less, and the particle size distribution indicator A represented by D84/D16 is 1.70 or more and 2.60 or less.

Abstract: A toner including: a toner particle, wherein the toner particle contains a binder resin, a compound represented by formula (1) below, and a compound in which at least a compound represented by formula (2) below and a compound represented by formula (3) below are in solid solution. In formula (1), R1, R2, R3, and R6 each independently represent an alkyl group or aryl group, and R4 and R5 each independently represent an aryl group, acyl group, or alkyl group, or R4 is bonded to R5 to form a cyclic organic functional group that contains R4, R5, and the nitrogen atom to which R4 and R5 are bonded.

Abstract: According to the present invention, in a toner including a toner particle containing a binder resin and a low molecular aromatic hydrocarbon, the binder resin contains a polyester resin, at least one kind of a unit derived from an aromatic monocarboxylic acid and a unit derived from an aromatic monoalcohol is contained, and the low molecular aromatic hydrocarbon has 1 or more and 4 or less benzene rings, and has a melting point of 60° C. or more and 120° C. or less.

Abstract: A toner including: a toner particle, wherein the toner particle contains a binder resin, a compound represented by formula (1) below, and a compound in which at least a compound represented by formula (2) below and a compound represented by formula (3) below are in solid solution. In formula (1), R1, R2, R3, and R6 each independently represent an alkyl group or aryl group, and R4 and R5 each independently represent an aryl group, acyl group, or alkyl group, or R4 is bonded to R5 to form a cyclic organic functional group that contains R4, R5, and the nitrogen atom to which R4 and R5 are bonded.

Abstract: Provided is a stable pharmaceutical composition comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants, or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.

Abstract: A toner having chargeability and fluidity that do not change to a great extent is provided. The toner includes toner particles containing a binder resin and includes inorganic fine particles A, wherein the shape factor SF-2 of primary particles of the inorganic fine particles A is 116 or less, and regarding the particle size distribution on a volume basis of the inorganic fine particles A on the toner particle surfaces, the particle diameter when a cumulative value from the small particle side reaches 16% by volume is denoted as D16, the particle diameter when a cumulative value reaches 50% by volume is denoted as D50, and the particle diameter when a cumulative value reaches 84% by volume is denoted as D84, D50 is 80 nm or more and 200 nm or less, and the particle size distribution indicator A represented by D84/D16 is 1.70 or more and 2.60 or less.

Abstract: Provided is a toner including a toner particle that contains a toner base particle containing a binder resin and a wax, and a coating layer containing a 1,2-polybutadiene resin at the surface of the toner base particle, wherein the coverage ratio of the toner base particle by the coating layer is at least 50%.

Abstract: Provided is a toner having a toner particle including a binder resin and a colorant, wherein the colorant includes a compound represented by Formula (1) below, a crystal of the compound in the toner particle has a diffraction peak with a full width at half maximum of at least 0.400° and not more than 0.440° in a range of a diffraction angle 2? of at least 5.0° and not more than 6.0° in an X-ray diffraction spectrum using CuK? rays, in Formula (1), X1 and X2 each independently represent a hydrogen atom, a chlorine atom or a methyl group.

Abstract: According to the present invention, in a toner including a toner particle containing a binder resin and a low molecular aromatic hydrocarbon, the binder resin contains a polyester resin, at least one kind of a unit derived from an aromatic monocarboxylic acid and a unit derived from an aromatic monoalcohol is contained, and the low molecular aromatic hydrocarbon has 1 or more and 4 or less benzene rings, and has a melting point of 60° C. or more and 120° C. or less.